www.scottishmedicines.org.uk

Collaborative Advice Document

SMC2550

remdesivir powder for concentrate for solution for infusion (Veklury®)

Gilead Sciences Ltd.

08 May 2024 (last updated 26 February 2026)

The Scottish Medicines Consortium (SMC) collaborated with the National Institute for Health and Care Excellence (NICE) and following review by the SMC Executive, SMC advises NHS boards and Area Drug and Therapeutics Committees (ADTCs) on the use of the above product in NHSScotland. The collaboration includes an update to remove sotrovimab because the company has discontinued manufacturing, supply, distribution and marketing of sotrovimab in the UK (update published February 2026). The advice is as follows:

ADVICE: following SMC collaboration with NICE on *TA971: remdesivir and tixagevimab plus cilgavimab for treating COVID-19.*

remdesivir (Veklury®) is accepted for restricted use within NHSScotland.

Indication under review: treatment of COVID-19 in:

- adults and paediatric patients (at least 4 weeks of age and weighing at least 3 kg) with pneumonia requiring supplemental oxygen (low- or high-flow oxygen or other non-invasive ventilation at start of treatment).
- adults and paediatric patients (weighing at least 40 kg) who do not require supplemental oxygen and who are at increased risk of progressing to severe COVID-19.

SMC restriction: as an option for treating COVID-19 in hospitals in:

- adults, only if they have a high risk of serious illness (risk factors as defined in section 5 of NICE's technology appraisal of nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19).
- babies, children and young people, only if they:
    - are aged 4 weeks to 17 years and weigh at least 3 kg, and have pneumonia and need supplemental oxygen, or
    - weigh at least 40 kg and have a high risk of serious illness (risk factors as defined in section 5 of NICE's technology appraisal guidance on nirmatrelvir plus ritonavir and tocilizumab for treating COVID-19).

Full details of the assessment and recommendations can be found at Overview | Remdesivir and tixagevimab plus cilgavimab for treating COVID-19 | Guidance | NICE.

This advice applies only in the context of an approved NHSScotland Patient Access Scheme (PAS) arrangement delivering the cost-effectiveness results upon which the decision was based, or a PAS/ list price that is equivalent or lower.

A budget impact template is provided in confidence to NHS boards to enable them to estimate the predicted budget for medicines accepted for use.

Advice context:

No part of this advice may be used without the whole of the advice being quoted in full.

This advice represents the view of the Scottish Medicines Consortium and was arrived at following collaboration with NICE. It is provided to inform the considerations of Area Drug and Therapeutics Committees and NHS boards in Scotland in determining medicines for local use or local formulary inclusion. This advice does not override the individual responsibility of health professionals to make decisions in the exercise of their clinical judgement in the circumstances of the individual patient, in consultation with the patient and/or guardian or carer.

Chair
Scottish Medicines Consortium